Skip to content

Redmile Group, LLC 13F Holdings · Q2 2026

Redmile Group, LLC reported 39 securities worth $1.49B in its SEC 13F filing for Q2 2026 (period ended 2026-06-30). Top holdings: SRRK (15.92%), KRYS (15.77%), STOK (8.67%). Among its top 25 positions this quarter: 1 new, 5 added, 15 trimmed.

RankTickerCompanyValue% PortfolioSharesAction
1SRRKSCHOLAR ROCK HLDG CORP$237.1M15.92%4.3MTrimmed
2KRYSKRYSTAL BIOTECH INC$234.9M15.77%632,005Trimmed
3STOKSTOKE THERAPEUTICS INC$129.1M8.67%3.9MTrimmed
4IMNMIMMUNOME INC$104.1M6.99%4.9MTrimmed
5NRIXNURIX THERAPEUTICS INC$98.8M6.64%4.1MTrimmed
6ABSIABSCI CORPORATION$78.1M5.24%6.7MTrimmed
7ANNXANNEXON INC$67.8M4.55%11.9MTrimmed
8RGNXREGENXBIO INC$52.3M3.51%4.4MHold
9STTKSHATTUCK LABS INC$47.8M3.21%6.9MAdded
10NGNENEUROGENE INC$44.4M2.98%1.4MTrimmed
11BEAMBEAM THERAPEUTICS INC$40.0M2.68%1.2MTrimmed
12AGMBAGOMAB THERAPEUTICS NV$35.5M2.38%2.7MAdded
13FATEFATE THERAPEUTICS INC$34.8M2.33%12.9MHold
14IDYAIDEAYA BIOSCIENCES INC$23.9M1.60%640,202Added
15SLNSILENCE THERAPEUTICS PLC$23.8M1.60%2.2MHold
16COGTCOGENT BIOSCIENCES INC$19.5M1.31%503,321Trimmed
17SLDBSOLID BIOSCIENCES INC$19.5M1.31%1.9MTrimmed
18NUVBNUVATION BIO INC$17.2M1.16%3.0MTrimmed
19CLDXCELLDEX THERAPEUTICS INC NEW$16.1M1.08%433,921Added
20CLYMCLIMB BIO INC$16.0M1.07%1.2MNew
21ALXOALX ONCOLOGY HLDGS INC$15.3M1.03%7.4MTrimmed
22BMRNBIOMARIN PHARMACEUTICAL INC$15.2M1.02%265,169Added
23XENEXENON PHARMACEUTICALS INC$13.8M0.93%229,374Trimmed
24ZYMEZYMEWORKS INC$12.9M0.86%491,654Hold
25ADCTADC THERAPEUTICS SA$12.3M0.83%11.5MTrimmed

Source: SEC Form 13F filings · as of 2026-06-30

Every position in this 13F-HR, with its change from the prior quarter.

13F holdings, latest quarter

SourceSEC EDGAR13F-HR